Apple Stumbles in Court as $634 Million Apple Watch Judgment Survives
Yahoo Finance ·
Apple Stumbles in Court as $634 Million Apple Watch Judgment Survives Nauman Khan Wed, July 22, 2026 at 9:11 AM EDT 1 min read AAPL DHR This article first appeared on GuruFocus . Apple ( NASDAQ:AAPL ) has lost its attempt to set aside a $634 million jury award tied to a patent dispute with Masimo over blood oxygen monitoring technology used in Apple Watch devices. A California federal judge ruled that Apple improperly used two of 14 trade secrets asserted by Masimo, but declined to issue an injunction against Apple. The court also found Masimo was not entitled to monetary damages related to the trade secret claims, narrowing part of the medical technology company's case. Warning! GuruFocus has detected 6 Warning Signs with TSLA. Is AAPL fairly valued? Test your thesis with our free DCF calculator. Masimo, now part of Danaher (DHR), had sought up to $3.1 billion in damages connected with the trade secret allegations. Following the ruling, Masimo filed a notice of appeal challenging the court's decision on those claims. Apple has maintained that its engineers independently developed the health-monitoring capabilities incorporated into Apple Watch products. The latest ruling leaves the $634 million patent verdict in place while the dispute continues through the appeals process. Apple shares edged about 0.4% higher in regular trading on Tuesday, while Danaher shares fell nearly 11% following separate quarterly earnings results and guidance.
AI 시장 분석
Apple's attempt to invalidate a $634 million damages ruling in its patent lawsuit with Masimo has failed. A California federal court ruled that Apple improperly used trade secrets related to blood oxygen monitoring technology. While this ruling imposes a financial burden on Apple, it avoided the worst-case scenario by dodging a preliminary injunction on sales.
하락 영향
- Big Tech — The upholding of the $634 million patent damages ruling highlights Apple's legal cost burden and judicial risks, negatively impacting short-term investor sentiment.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
438 participants
Related News
- Thermo Fisher Scientific Q2 2026 Earnings Preview
- OpenAI Presence helps enterprises deploy more reliable agents within guardrails
- Crude oil extends gains as hopes fade for peace talks, Rubio says Iran not serious
- Intel's sky-high rally put to the test as expectations soar
- Airbus lands new airline orders as Farnborough focus extends beyond commercial jets
- Crude inventory rises by 2M barrels for the week ended July 17 – EIA
